National Institute of Allergy and Infectious Disease Awards Grant to ResVita Bio
ResVita will use the money to develop a treatment for severe atopic dermatitis.
ResVita Bio announced that it has been awarded a $250,000 grant from the National Institute of Allergy and Infectious Disease (NIAID). The grant, titled the Phase 1 Small Business Innovation Research grant, will be used to develop a cell therapy for treating severe atopic dermatitis.
In a press release, ResVita Bio’s CEO Amin Zargar, PhD, said, “Within a year, we have been honored to receive two innovation grants from the NIH to develop therapies for both Netherton Syndrome, an orphan disease, and severe atopic dermatitis through our topical cell therapy approach. This is in addition to our Rare Pediatric Disease Designation for Netherton Syndrome from the FDA, setting the stage for the entry of our therapy into the clinic in 2025."
The treatment, called RVB-101, utilizes genetically engineered cells that are applied to the skin using a topical moisturizer. The cells then colonize the skin and repair the epidermal barrier and alleviate inflammation.
Source
(September 18, 2023); PR Newswire; ResVita Bio Receives NIH Grant to Develop Breakthrough Treatment for Severe Atopic Dermatitis; https://www.prnewswire.com/news-releases/resvita-bio-receives-nih-grant-to-develop-breakthrough-treatment-for-severe-atopic-dermatitis-301929130.html
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
